Neuroendocrine Tumor Pipeline Shows Strong Growth with 75+ Therapies in Development
Key Insights
The global neuroendocrine tumor (NET) pipeline comprises over 70 key companies developing 75+ treatment therapies across various clinical phases, according to DelveInsight (search)'s 2025 assessment.
Recent FDA approvals include Cabometyx for pancreatic and extra-pancreatic NETs in March 2025, and Belzutifan for pheochromocytoma (search)/paraganglioma (search) in October 2025, demonstrating significant clinical progress.
ITM-11 showed statistically significant improvement in progression-free survival compared to everolimus in Phase III COMPETE study for gastroenteropancreatic NETs, highlighting the potential of targeted radiotherapy approaches.
The neuroendocrine tumor (NET) treatment landscape is experiencing unprecedented growth, with over 70 companies actively developing 75+ therapeutic candidates across multiple clinical phases, according to DelveInsight (search)'s comprehensive 2025 pipeline assessment.
Recent FDA Approvals Signal Market Momentum
The regulatory environment has shown strong support for NET therapies, with several significant approvals in early 2025. In March 2025, the FDA approved Cabometyx (cabozantinib) for two new indications: treatment of adults and adolescents aged 12 and older with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (search) (pNET), and for the same population with extra-pancreatic neuroendocrine tumors (epNET).
Belzutifan (Welireg) received FDA approval in October 2025 for advanced pheochromocytoma (search) or paraganglioma (search) (PPGL) following positive results from a single-arm Phase II trial. The study demonstrated that 26% of 72 participants achieved confirmed objective responses, with an additional 58% experiencing stable disease, resulting in an overall disease control rate of 85%, according to Dr. Camilo Jimenez of MD Anderson Cancer Center.
Breakthrough in Targeted Radiotherapy
ITM Isotope Technologies Munich (search) SE reported encouraging topline findings from its Phase III COMPETE study in February 2025. The trial evaluated ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiotherapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (search) (GEP-NETs). ITM-11 delivered a statistically significant and clinically meaningful improvement in progression-free survival compared to everolimus, a current standard treatment option.
Diverse Pipeline Across Multiple Mechanisms
The NET pipeline encompasses a broad range of therapeutic approaches, including established treatments and novel mechanisms. Key therapies under development include LUTATHERA (lutetium Lu 177 dotatate) from Advanced Accelerator Applications/Novartis, SOMATULINE DEPOT (search) (lanreotide) from Ipsen Biopharmaceuticals (search), and AFINITOR (everolimus) from Novartis.
Emerging candidates span various molecular types including monoclonal antibodies, peptides, polymers, small molecules, and gene therapy approaches. Routes of administration include oral, parenteral, intravenous, subcutaneous, and topical formulations, providing flexibility for different patient populations and clinical scenarios.
Market Drivers and Challenges
The NET market growth is fueled by rising disease prevalence and increasing research and development activities. However, the market faces obstacles including limited awareness, under-diagnosis, and the inherent heterogeneity and complexity of neuroendocrine tumors (search).
Major pharmaceutical companies driving innovation in this space include Pfizer, Takeda Oncology, Hutchison MediPharma, Camurus (search), ITM Solucin, Radiomedix, Clarity Pharmaceuticals, Merck (search) & Co, RayzeBio (search), and Exelixis, among others.
Clinical Trial Landscape
The pipeline includes therapies across all development stages, from discovery and preclinical phases through late-stage Phase III trials. Notable candidates include CAM2029 from Camurus (search), RYZ101 from RayzeBio (search), and various radiopharmaceutical approaches utilizing lutetium-177 and other isotopes.
The Cabozantinib Phase 3 CABINET trial demonstrated significant improvement in progression-free survival compared to placebo in patients with extrapancreatic NETs from the gastrointestinal tract, with consistent benefits across various clinical subgroups except in patients with non-midgut GI primary tumors.
Future Outlook
The NET treatment landscape is positioned for substantial transformation over the coming years, driven by the anticipated launch of multiple novel therapies with improved efficacy profiles. The combination of regulatory support, diverse therapeutic approaches, and strong industry investment suggests a promising future for patients with these rare but challenging cancers.